Home
Mohn Cancer Research Laboratory

News archive for Mohn Cancer Research Laboratory

A new study published in JAMA Oncology (September 2022) shows that BRCA1 methylation in early embryotic life leads to increased cancer risk in the adult.
In an interview with journalist Marit Aaby Vebenstad (published 28.06.2022 in the Norwegian oncology journal Brystkreft), Per Eystein Lønning from Mohn Cancer Research Laboratory talks about the promising effect of Lynparza as monotherapy in the treatment of triple negative breast cancer in the clinical trial Petremac.
Norwegian newspaper Dagbladet (04.06.2022 (digital edition) and 21.06.2022 (paper edition)) and Swedish newspaper Expressen (12.06.2022) both mention a research project that is a collaboration between the Breast Cancer Group at Mohn Cancer Research Laboratory and the Women's Health Initiative (WHI) in USA. The research study describes a new type of mechanism that is triggered during early... Read more
In an interview with journalist Julie Kalveland from Dagens Medisin (04.06.2022) Professor Per Eystein Lønning shares the most important findings from a Norwegian-American collaboration study on BRCA1-methylation in breast and ovarian cancer. These findings were presented orally by Lønning at ASCO (03.06.2022).
Research on PARP inhibitors carried out at Mohn Cancer Research Laboratory and KG Jebsen's center for genome-directed cancer therapy receives attention in the international press after publication in the Annals of Oncology.
Bergens Tidende shares the story of Elisabeth Thomassen, who receives support from the am-car community to raise money to try treatment in the USA.
Bergens Tidende shares the story of Aud and Kristel on 5 November; two ladies who have both been treated for breast cancer.
In December 2018, professor Per Eystein lønning and senior researcher Stian Knappskog each received a new research grant of 10 mill NOK from the Norwegian Research Council under the FRIMEDBIO program. Since only 5-10% of all applications to this program are funded, we are very happy that two groups within our research environment received such grants.
In December 2018, professor Per Eystein lønning and senior researcher Stian Knappskog each received a new research grant of 10 mill NOK from the Norwegian Research Council under the FRIMEDBIO program. Since only 5-10% of all applications to this program are funded, we are very happy that two groups within our research environment received such grants.